Protocols & Players
This recent US-approved 2L+ regimen combines a BCMA-directed BsAb with an anti-CD38 mAb
What is teclistamab and daratumumab (MajesTEC-3)
Unlike the USPI, which specifies 4 prior lines, the SmPC requires ELREXFIO be used after this
What is 3 prior therapies
This BsAb is increasingly used as a bridging strategy to CAR T-cell therapy
What is talquetamab
According to KOL insights, this type of 2L patient may be preferred for BsAb monotherapy
What is anti-CD38-refractory patients (also accepted: frail patients)
This is the control arm in MagnetisMM-5
After 44 months of follow-up with ELREXFIO, this efficacy endpoint has still not been reached
What is duration of response
As of May 2026, median PFS has not yet been reached for this BsAb
What is linvoseltamab
In addition to concerns with infection risk, being confined to patients who are “ultra frail” or have significant comorbidities, and T-cell exhaustion, KOLs have identified this as a key perceived weakness of BsAb monotherapy
What is long-term durability
Compared with MagnetisMM-32, this is how the patient population differs in MagnetisMM-5
MagnetisMM-5: ≥1 prior LOT, including lenalidomide and a PI
MagnetisMM-32: 1-4 prior LOTs, including an anti-CD38 mAb and lenalidomide
Per the ELREXFIO SmPC, patients may switch to monthly dosing after at least this many weeks of treatment on an every-2-week dosing schedule
What is 24 weeks
Apart from elranatamab, this BsAb/BsAbs is/are being evaluated as a monotherapy in 2L+ MM
What is teclistamab and linvoseltamab
Some HCPs consider the teclistamab + daratumumab regimen a triplet because of this, which may contribute to increased financial toxicity
What is IVIg use